Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccharide-stimulated macrophages

Critical Care Medicine

Volumn 43, Issue 11, 2015, Pages e508-e520

  Wang, Qiang ^a   Yokoo, Hiroki ^a,b   Takashina, Michinori ^a   Sakata, Kimimasa ^a   Ohashi, Wakana ^a   Abedelzaher, Lobna A ^a   Imaizumi, Takahiro ^a   Sakamoto, Takuya ^a   Hattori, Kohshi ^b   Matsuda, Naoyuki ^c,d   Hattori, Yuichi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HAMAMATSU UNIVERSITY   (Japan)

Author keywords

Hemodynamic dysfunction; High mobility group box 1; Inflammation; Levosimendan; Macrophages; Nuclear factor B; Pimobendan; Sepsis

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEVOSIMENDAN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PIMOBENDAN; PROTEIN KINASE B; RHO KINASE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; CYTOKINE; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CELL INFILTRATION; CELL NUCLEUS; CELL STIMULATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EXTRACELLULAR SPACE; GENE EXPRESSION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HISTOPATHOLOGY; HYPOTENSION; INFLAMMATORY CELL; LUNG ALVEOLUS CELL; LUNG EDEMA; LUNG INJURY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; PERITONEAL CAVITY; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUNEL ASSAY; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CECUM; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LIGATION; METABOLISM; MORTALITY; NEEDLE BIOPSY; NONPARAMETRIC TEST; PATHOLOGY; PROCEDURES; RANDOMIZATION; REFERENCE VALUE; SEPSIS; SURGERY; SURVIVAL RATE; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CECUM; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYDRAZONES; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; LIGATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; PYRIDAZINES; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; SEPSIS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 84944450326     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001269     Document Type: Article

References (56)

1. Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Defnitions Conference. Crit Care Med 2003; 31:1250-1256
2. Riedemann NC, Guo RF, Ward PA: The enigma of sepsis. J Clin Invest 2003; 112:460-467
3. O'Brien JM Jr, Ali NA, Aberegg SK, et al: Sepsis. Am J Med 2007; 120:1012-1022
4. Beal AL, Cerra FB: Multiple organ failure syndrome in the 1990s. Systemic infammatory response and organ dysfunction. JAMA 1994; 271:226-233
5. Vincent JL, Sakr Y, Sprung CL, et al; Sepsis Occurrence in Acutely Ill Patients Investigators: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34:344-353
6. Angus DC, Pereira CA, Silva E: Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 2006; 6:207-212
7. Blinks JR, Endoh M: Modifcation of myofbrillar responsiveness to Ca++ as an inotropic mechanism. Circulation 1986; 73(Suppl III):III-85-III-98
8. Endoh M: Cardiac Ca2+ signaling and Ca2+ sensitizers. Circ J 2008; 72:1915-1925
9. Kass DA, Solaro RJ: Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006; 113:305-315
10. Frishman WH: Advances in positive inotropic therapy: Levosimendan. Crit Care Med 2003; 31:2408-2409
11. Papp Z, Csapó K, Pollesello P, et al: Pharmacological mechanisms contributing to the clinical effcacy of levosimendan. Cardiovasc Drug Rev 2005; 23:71-98
12. Matejovic M, Krouzecky A, Radej J, et al: Successful reversal of resis-tent hypodynamic septic shock with levosimendan. Acta Anaesthesiol Scand 2005; 49:127-128
13. Morelli A, De Castro S, Teboul JL, et al: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005; 31:638-644
14. Paraskevaidis IA, Parissis JT, Th Kremastinos D: Anti-infammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: A novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents 2005; 3:243-247
15. Parissis JT, Farmakis D, Kremastinos DT: Anti-infammatory effects of levosimendan in decompensated heart failure: Impact on weight loss and anemia. Am J Cardiol 2005; 95:923-924
16. Oldner A, Konrad D, Weitzberg E, et al: Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 2001; 29:2185-2193
17. Faivre V, Kaskos H, Callebert J, et al: Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharide-treated rabbits. Anesthesiology 2005; 103:514-521
18. Scheiermann P, Ahluwalia D, Hoegl S, et al: Effects of intravenous and inhaled levosimendan in severe rodent sepsis. Intensive Care Med 2009; 35:1412-1419
19. Hubbard WJ, Choudhry M, Schwacha MG, et al: Cecal ligation and puncture. Shock2005; 24(Suppl 1):52-57
20. Murai K, Seino Y, Kimata N, et al: Effcacy and limitations of oral inotropic agents for the treatment of chronic heart failure. Int Heart J 2013; 54:75-81
21. Matsuda N, Yamamoto S, Yokoo H, et al: Nuclear factor-kappaB decoy oligodeoxynucleotides ameliorate impaired glucose tolerance and insulin resistance in mice with cecal ligation and puncture-induced sepsis. Crit Care Med 2009; 37:2791-2799
22. Oishi H, Takano K, Tomita K, et al: Olprinone and colforsin daropate alleviate septic lung infammation and apoptosis through CREB-independent activation of the Akt pathway. Am J Physiol Lung Cell Mol Physiol 2012; 303:L130-L140
23. Takebe M, Oishi H, Taguchi K, et al: Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis. J Surg Res 2014; 187:559-570
24. Kivikko M, Antila S, Eha J, et al: Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; 40:465-471
25. Takano K, Yamamoto S, Tomita K, et al: Successful treatment of acute lung injury with pitavastatin in septic mice: Potential role of glucocorticoid receptor expression in alveolar macrophages. J Pharmacol Exp Ther 2011; 336:381-390
26. Taguchi K, Sakata K, Ohashi W, et al: Tonic inhibition by G protein-coupled receptor kinase 2 of Akt/endothelial nitric-oxide synthase signaling in human vascular endothelial cells under conditions of hyperglycemia with high insulin levels. J Pharmacol Exp Ther 2014; 349:199-208
27. Hojyo S, Fukada T, Shimoda S, et al: The zinc transporter SLC39A14/ZIP14 controls G-protein coupled receptor-mediated signaling required for systemic growth. PLoS One 2011; 6:e18059
28. Matsuda N, Yamamoto S, Takano K, et al: Silencing of fas-associated death domain protects mice from septic lung infammation and apoptosis. Am J Respir Crit Care Med 2009; 179: 806-815
29. Liu SF, Malik AB: NF-kappa B activation as a pathological mechanism of septic shock and infammation. Am J Physiol Lung Cell Mol Physiol 2006; 290:L622-L645
30. Ghosh S, Hayden MS: New regulators of NF-kappaB in infammation. Nat Rev Immunol 2008; 8:837-848
31. Kaminska B: MAPK signalling pathways as molecular targets for anti-infammatory therapy-from molecular mechanisms to therapeutic benefts. Biochim Biophys Acta 2005; 1754:253-262
32. Lee YG, Lee J, Byeon SE, et al: Functional role of Akt in macro-phage-mediated innate immunity. Front Biosci (Landmark Ed) 2011; 16:51 7-530
33. Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5:331-342
34. Andersson U, Tracey KJ: HMGB1 is a therapeutic target for sterile infammation and infection. Annu Rev Immunol 2011; 29:139-162
35. Archan S, Toller W: Levosimendan: Current status and future prospects. Curr Opin Anaesthesiol 2008; 21:78-84
36. Fernandes CJ Jr, de Assuncao MS: Myocardial dysfunction in sepsis: A large, unsolved puzzle. Crit Care Res Pract 2012; 2012:896430
37. Bhatia M, Moochhala S: Role of infammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 2004; 202:145-156
38. Ayala A, Perl M, Venet F, et al: Apoptosis in sepsis: Mechanisms, clinical impact and potential therapeutic targets. Curr Pharm Des 2008; 14:1853-1859
39. Hattori Y, Takano K, Teramae H, et al: Insights into sepsis therapeutic design based on the apoptotic death pathway. J Pharmacol Sci 2010; 114:354-365
40. Erbüyün K, Vatansever S, Tok D, et al: Effects of levosimendan and dobutamine on experimental acute lung injury in rats. Acta Histochem 2009; 111:404-414
41. Campbell KJ, Perkins ND: Regulation of NF-kappaB function. Biochem Soc Symp 2006; 73:165-180
42. Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16:225-260
43. Sareila O, Korhonen R, Auvinen H, et al: Effects of levo-and dextrosi-mendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to infammatory stimuli. Br J Pharmacol 2008; 155:884-895
44. Sweet MJ, Hume DA: Endotoxin signal transduction in macrophages. J Leukoc Biol 1996; 60:8-26
45. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 2001; 13:85-94
46. Guha M, Mackman N: The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of infammatory mediators in human monocytic cells. J Biol Chem 2002; 277:32124-32132
47. Zhan J, Liu Y, Zhang Z, et al: Effect of penehyclidine hydrochloride on expressions of MAPK in mice with CLP-induced acute lung injury. Mol Biol Rep 2011; 38:1909-1914
48. Li W, Fan T, Zhang Y, et al: Effect of chelerythrine against endo-toxic shock in mice and its modulation of infammatory mediators in peritoneal macrophages through the modulation of mitogen-activated protein kinase (MAPK) pathway. Infammation 2012; 35:1814-1824
49. Shao J, Li Y, Wang Z, et al: 7b, a novel naphthalimide derivative, exhibited anti-infammatory effects via targeted-inhibiting TAK1 following down-regulation of ERK1/2-and p38 MAPK-mediated activation of NF-KB in LPS-stimulated RAW264.7 macrophages. Int Immunopharmacol 2013; 17:216-228
50. Andersson U, Wang H, Palmblad K, et al: High mobility group 1 protein (HMG-1) stimulates proinfammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192:565-570
51. Ueno H, Matsuda T, Hashimoto S, et al: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004; 170:1310-1316
52. Karlsson S, Pettilä V, Tenhunen J, et al: HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 2008; 34:1046-1053
53. Gardella S, Andrei C, Ferrera D, et al: The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3:995-1001
54. Bonaldi T, Talamo F, Scaffdi P, et al: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22:5551-5560
55. Hasan Z, Palani K, Zhang S, et al: Rho kinase regulates induction of T-cell immune dysfunction in abdominal sepsis. Infect Immun 2013; 81:2499-2506
56. Vincent JL, Gerlach H: Fluid resuscitation in severe sepsis and septic shock: An evidence-based review. Crit Care Med 2004; 32:S451-S454